Charles Bisgaier - Gemphire Therapeutics Insider

Gemphire Therapeutics Inc -- USA Stock  

USD 7.01  0.26  3.58%

Co-Founder, Chief Scientific Officer

Dr. Charles L. Bisgaier Ph.D., is Chairman of the Board, Chief Scientific Officer of the Company
Age: 62  Founder Since 2014  Ph.D    
Bisgaier was an Associate Research Fellow in the Department of Vascular and Cardiac Disease at WarnerLambert/ParkeDavis. There he participated in the discovery and/or development of gemfibrozil, atorvastatin and gemcabene . Subsequently, Dr. Bisgaier cofounded the first Esperion Therapeutics, which was then acquired by Pfizer. At Pfizer he then served as the Senior Director of Pharmacology at the Esperion Division of Pfizer Global Research and Development. Notably, he was a major influence in the discovery, research and/or development of many small molecules with potential utility for metabolic syndrome including ETC1002 which was licensed by the new Esperion from Pfizer, as well as HDLtherapy product candidates, such as ApoAI Milano which was also licensed by The Medicines Company from Pfizer

Charles Bisgaier Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (70.7) % which means that it has lost $70.7 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (218.53) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 9.96 M in liabilities with Debt to Equity (D/E) ratio of 100.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gemphire Therapeutics Inc has Current Ratio of 4.08 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver diseasenon-alcoholic steatohepatitis . It is developing gemcabene , an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. Gemphire Therapeutics is traded on NASDAQ General Markets in USA.Gemphire Therapeutics Inc (GEMP) is traded on NASDAQ General Markets in USA. It is located in MICHIGAN, U.S.A and employs 17 people. Gemphire Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Focused Opportunities Now

Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Hide  View All  NextLaunch Focused Opportunities
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Gemphire Therapeutics Inc to your portfolio

Top Management

Gemphire Therapeutics Inc Leadership Team
Charles Bisgaier, Founder, Ph.D
Mina Sooch, CEO, MBA
Kenneth Kousky, Director
Andrew Sassine, Director, MBA
Jeffrey Mathiesen, CFO
Seth Reno, Executive, MBA
Pedro Lichtinger, Director, MBA
Steven Gullans, CEO, Ph.D
David Lowenschuss, Founder
Kent Hawryluk, Director, MBA
Lee Golden, Executive, Ph.D

Stock Performance

Gemphire Therapeutics Performance Indicators